← The Wire
XFORNasdaq
X4 Pharmaceuticals, Inc
Biological Products, (No Diagnostic Substances) · DE · CIK 1501697
Develops and commercializes novel therapeutics for rare hematology diseases, including mavorixafor for WHIM syndrome and chronic neutropenia
red 8-K · 90d
$377M
Market cap
$4.23
Last close
+5.2%
1D
+2.7%
5D
592K
Volume
Price · last 39 sessions+0.5%
May 4L $3.64 · H $4.50Jun 29
249
Total filings
May 13, 2026
Last filing
12/31
Fiscal year end
8-K/AExecutive Change · Shareholder VoteMay 13, 20268-KExecutive Change · Shareholder VoteMay 12, 202610-Q10-QMay 6, 2026DEFA14ADEFA14AMar 20, 2026DEF 14ADEF 14AMar 20, 202610-K10-KMar 17, 202610-Q10-QNov 5, 20258-KResults of OperationsNov 5, 20258-KMaterial AgreementOct 27, 2025424B5424B5Oct 24, 2025424B5424B5Oct 23, 20258-KExecutive Change · Exit / Disposal CostsSep 17, 20258-KExecutive ChangeAug 25, 20258-KMaterial Agreement · Equity IssuanceAug 13, 20258-KExecutive Change · Material AgreementAug 12, 202510-Q10-QAug 8, 20258-KMaterial AgreementJun 23, 2025424B5424B5Jun 23, 20258-KShareholder VoteJun 11, 202510-Q10-QMay 1, 20258-KResults of Operations · Reg FD DisclosureMay 1, 2025DEF 14ADEF 14AApr 25, 2025DEFA14ADEFA14AApr 25, 20258-KBylaw Amendment · Company UpdateApr 24, 20258-KShareholder VoteApr 18, 202510-K10-KMar 26, 20258-KResults of OperationsMar 25, 2025DEF 14ADEF 14AMar 24, 20258-KCompany UpdateMar 3, 20258-KExit / Disposal Costs · Reg FD DisclosureFeb 6, 20258-KMaterial Agreement · Reg FD DisclosureJan 13, 202510-Q10-QNov 13, 20248-KReg FD Disclosure · Company UpdateNov 13, 20248-KResults of OperationsNov 13, 2024SC 13GSC 13GNov 8, 2024SC 13GSC 13GOct 22, 20248-KDelisting NoticeAug 16, 20248-KReg FD DisclosureAug 9, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 8, 20248-KReg FD DisclosureJul 19, 20248-KReg FD Disclosure · Company UpdateJun 27, 20248-KShareholder VoteJun 11, 20248-KReg FD DisclosureMay 22, 20248-KExecutive Change · Material AgreementMay 9, 202410-Q10-QMay 7, 20248-KResults of OperationsMay 7, 2024DEFA14ADEFA14AApr 29, 2024DEF 14ADEF 14AApr 29, 20248-KReg FD Disclosure · Company UpdateApr 29, 20248-KReg FD Disclosure · Company UpdateApr 29, 20248-KCompany UpdateApr 5, 20248-KReg FD DisclosureApr 1, 202410-K10-KMar 21, 20248-KResults of OperationsMar 21, 2024SC 13GSC 13GFeb 14, 2024SC 13GSC 13GJan 31, 20248-KReg FD DisclosureJan 8, 20248-KReg FD DisclosureNov 27, 20238-KDelisting NoticeNov 14, 202310-Q10-QNov 9, 20238-KResults of OperationsNov 9, 20238-KCompany UpdateOct 31, 20238-KExecutive Change · Reg FD DisclosureOct 18, 20238-KCompany UpdateSep 5, 202310-Q10-QAug 10, 20238-KResults of OperationsAug 10, 20238-KMaterial Agreement · New Debt / ObligationAug 3, 2023SC 13GSC 13GJun 16, 20238-KShareholder VoteJun 15, 20238-KReg FD DisclosureJun 1, 20238-KMaterial Agreement · Equity IssuanceMay 16, 202310-Q10-QMay 4, 20238-KReg FD DisclosureMay 4, 20238-KResults of OperationsMay 4, 20238-KAcquisition / DispositionMay 4, 2023DEFA14ADEFA14AApr 27, 2023DEFA14ADEFA14AApr 25, 2023DEF 14ADEF 14AApr 25, 20238-KReg FD DisclosureMar 21, 2023
Insider Activity
In the 90 days to Oct 23, 2025: 1 insider bought $250K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 23, 2025 | Craig Adam RExecutive Chairman | Buy | 86,206 | $2.90 | $250K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance